AYLA

In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Ayala Pharmaceuticals (AYLA - Research Report), with a price target of $12.00. The company's shares closed yesterday at $1.35.According to TipRanks, LeBoyer is a 4-star analyst with an average return of 12.2% and a 35.29% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as Ayala Pharmaceuticals, Tonix Pharma, and PDS Biotechnology.Currently, the analyst consensus on Ayala Pharmaceuticals is a Moderate Buy with an average price target of $12.00, implying a 788.89% upside from current levels. In a report released yesterday, H.C.
https://www.tipranks.com/news/blurbs/noble-financial-keeps-their-buy-rating-on-ayala-pharmaceuticals-ayla?utm_source=advfn.com&utm_medium=referral